Health Care/Hospital
Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast
* Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will ...
2022-01-28 22:00
5927
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...
2022-01-28 21:00
2309
Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease
MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple S...
2022-01-28 20:08
1884
"Don't forget leprosy" campaign gathers pace as World Leprosy Day approaches
TOKYO, Jan. 28, 2022 /PRNewswire/ -- Sasakawa Leprosy (Hansen's Disease) Initiative is collaborating with 32 organizations from 13 countries to promote the message "Don't forget leprosy" in the run-up to World Leprosy Day onJanuary 30. The international campaign includes awareness-raising events ...
2022-01-28 19:00
1626
Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD$2.3 billion * Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis * Expected to accelerate g...
2022-01-28 08:10
1672
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling$30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital...
2022-01-27 22:10
1462
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights: * NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow * New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases * New US composition of matter patent secures exclus...
2022-01-27 20:45
4571
I Peace's Cell Manufacturing Facility "Peace Engine Kyoto" now registered as U.S. FDA Drug Establishment
PALO ALTO, Calif., Jan. 26, 2022 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up, announced that its cell manufacturing facility is now listed on the FDA "Drug Establishments Current Registration Site." The registration recognizes I Peace's cell manufacturing f...
2022-01-27 01:00
1468
iMediSync Successfully Launches the Future of Tele-Medicare at CES 2022
SEOUL, South Korea, Jan. 26, 2022 /PRNewswire/ -- iMediSync, A biotech startup
company fromSeoul, South Korea, successfully debuted at CES 2022 to introduce
the new trend of digital healthcare under their motto – Overcome Mental
Pandemic in just 10 Min.
2022-01-26 22:00
3467
Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that it has entered into a Global License Agreement with Xiamen Biotime Biot...
2022-01-26 21:00
1318
China Jo-Jo Drugstores Granted Extension to Meet Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, Jan. 26, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that on J...
2022-01-26 21:00
3993
Hope Medicine Announces US FDA Clearance for Phase II Clinical Trial of A First-in-class Monoclonal Antibody, HMI-115, in Androgen Alopecia
SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for phase II study to evaluate HMI-115, a ...
2022-01-26 08:00
1639
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA
WUHAN, China and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the Company's le...
2022-01-25 22:00
1483
Daewoong Pharmaceutical Released Positive Phase 3 Topline Results for New Antidiabetic Drug
SEOUL, South Korea, Jan. 25, 2022 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) has confirmed promising phase 3 topline results that focuses on the therapeutic effects as an Enavogliflozin monotherapy and a combination therapy with Metformin.Daewoong's Enavogliflozin is an SGLT-2 inhibitor i...
2022-01-25 22:00
1414
KAZIA THERAPEUTICS TO PARTICIPATE IN EDISON GROUP'S GLOBAL HEALTHCARE 'OPEN HOUSE' VIRTUAL CONFERENCE
SYDNEY, Jan. 25, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be speaking at the Edison Group 'Open House' Event, to be held virtually from25-27 January 2022. Kazia ...
2022-01-25 21:00
2983
Senhwa's Pidnarulex Receives US FDA Fast Track Designation for the Treatment of Solid Tumors with BRCA1/2, PALB2 and other HR Gene Mutations
TAIPEI and SAN DIEGO, Jan. 25, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that the US Food and Drug Administration (FDA) has granted Fast Track...
2022-01-25 20:00
1714
Sequanta selects Olink® Explore 3072 to analyze new cohort study in China
SHANGHAI, Jan. 25, 2022 /PRNewswire/ -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that Sequanta Technologies, a leading multi-omics service provider based inChina, will use Olink® Explore 3072 to analyze the samples to serve a new large scale cohort study in China. Since 2021, Sequa...
2022-01-25 19:36
1259
2022 Japan Prize Laureates Announced
TOKYO, Jan. 25, 2022 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2022 Japan prize onJanuary 25. Prof. Katalin Kariko (Hungary/USA ) and Prof.Drew Weissman (USA) are co-winners of the Japan Prize in the field of "Materials and Production," and Prof.Christopher Field (USA...
2022-01-25 14:00
1430
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
2022-01-25 09:00
3085
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
SHENZHEN, China, Jan. 24, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and Phar...
2022-01-25 08:30
1362
Week's Top Stories
Most Reposted
MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
[Picked up by 331 media titles]
2024-05-23 10:00
SINGAPORE'S XSQUARE TECHNOLOGIES SECURES S$10.5M IN SERIES A FUNDING LED BY WAVEMAKER PARTNERS
[Picked up by 325 media titles]
2024-05-23 10:00Innomix and World Castle Association Pioneer LBMR project at Zhangbi Fortress
[Picked up by 321 media titles]
2024-05-20 13:48
Samsung Electronics Unveils Month-Long Celebration of Esports Events for Students in Southeast Asia
[Picked up by 320 media titles]
2024-05-21 08:00
Mitsui Bussan Secure Directions, Inc. launches Blackpanda IR Retainer, a cyber incident emergency response retainer service
[Picked up by 312 media titles]
2024-05-21 13:00
Most Read
Mitsui Bussan Secure Directions, Inc. launches Blackpanda IR Retainer, a cyber incident emergency response retainer service
2024-05-21 13:00
10312
Innomix and World Castle Association Pioneer LBMR project at Zhangbi Fortress
2024-05-20 13:48
9563
Samsung Electronics Unveils Month-Long Celebration of Esports Events for Students in Southeast Asia
2024-05-21 08:00
8757
Revolutionising Cardiac Care at Pantai Hospital Kuala Lumpur
2024-05-23 11:22
8451
Ferretti's first-quarter performance shines, with the new shipyard put into operation
2024-05-20 07:12
8132